InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Apimeds Pharmaceuticals US, Inc.

APUS Clue Score33
United States Fiscal year ends December CIK 0001894525
$5.02 -8.89% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $5.02 +169.89% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 9 May 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−0.7Net income−0.8EPS, diluted−0.17Fiscal year 2024Operating income−1.3Net income−1.4EPS, diluted−0.18Fiscal year 2025Operating income−11.9Net income−6.0EPS, diluted−0.55
FY2023FY2024FY2025
Operating income −0.7 −1.3 −11.9
Net income −0.8 −1.4 −6.0
Growth
EPS, diluted −0.17 −0.18 −0.55
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−0.6Fiscal year 2024Operating cash flow−0.7Fiscal year 2025Operating cash flow−8.9Capital expenditure−0.1Free cash flow−9.0
FY2023FY2024FY2025
Operating cash flow −0.6 −0.7 −8.9
Capital expenditure n/a n/a −0.1
Free cash flow n/a n/a −9.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.4Shareholders’ equity0.0Fiscal year 2024Cash0.0Shareholders’ equity−1.4Fiscal year 2025Cash1.6Shareholders’ equity153.3
FY2023FY2024FY2025
Cash 0.4 0.0 1.6
Shareholders’ equity 0.0 −1.4 153.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.1 n/a 1.6
0.6 1.3 10.3
−0.7 −1.3 −11.9
Growth
−0.8 −1.4 −6.0
Growth
Per share
−0.17 −0.18 −0.55
−0.17 −0.18 −0.55
Growth
4.6 7.9 10.9
n/a 7.9 10.9
Growth +37.7%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.